Search

Your search keyword '"Reizenstein P"' showing total 29 results
Start Over Author "Reizenstein P" Publisher wiley
29 results on '"Reizenstein P"'

10. Oxymetholone Treatment in Aregenerative Anaemia

Author

Hast, R., primary, Skårberg, K. O., additional, Engstedt, L., additional, Jameson, S., additional, Killander, A., additional, Lundh, B., additional, Reizenstein, P., additional, Udén, A. M., additional, and Wadman, B., additional

Published
2009
Full Text
View/download PDF

17. Induction of remission with l-asparaginase, cyclophosphamide, cytosine arabinoside, and prednisolone in adult patients with acute leukemia

Author

S. Franzén, L. Engstedt, Reizenstein P, Killander A, Håkan Mellstedt, B. Swedberg, S. Höglund, K.O. Skårberg, B. Gullbring, Jan Palmblad, A. M. Udén, D. Killander, Lockner D, Holm G, and Gösta Gahrton

Subjects
Cancer Research, medicine.medical_specialty, Asparaginase, Acute leukemia, Cyclophosphamide, business.industry, Nausea, Spontaneous remission, Gastroenterology, chemistry.chemical_compound, Endocrinology, Oncology, chemistry, Internal medicine, Vomiting, Cytarabine, Prednisolone, Medicine, medicine.symptom, business, medicine.drug
Abstract

Seventy-one adults with acute leukemia were randomized for treatment with a combination of cyclophosphamide, cytosine arabinoside, and prednisolone, with (CAPA) or without (CAP) the addition of L-asparaginase. Remissions were induced with CAPA in 9 patients (33%) with AML, and 8 patients (67%) with ALL, and with CAP in 10 patients (40%) with AML, and 4 patients (57%) with ALL. Thus, the addition of L-asparaginase did not improve the response significantly. The over-all complete remission rate was significantly higher in females (45%) than in males (23%), and the rate below 50 years of age tended to be higher (45%) than above this age (27%). There was a slight tendency for a longer first remission time in AML with L-asparaginase (284 days) than without (74 days), but no such difference between the two ALL groups. Hyper-sensitivity reactions, nausea, vomiting, psychiatric disturbances, and liver dys-function were more common side effects in patients treated with L-asparaginase.

Published
1974
Full Text
View/download PDF

18. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

Author

K.O. Skårberg, L. Engstedt, Göran Holm, S. Franzén, A. Dohlwitz, A. M. Udén, D. Killander, P. J. Moe, B. Gullbring, S. Höglund, D. Lockner, B. Wadman, Reizenstein P, Arne Holmgren, A. Killander, Håkan Mellstedt, Gösta Gahrton, Jan Palmblad, L. Åhström, B. Swedberg, and Leif Wide

Subjects
Adult, Cancer Research, Asparaginase, Time Factors, Antineoplastic Agents, Immunoglobulin E, chemistry.chemical_compound, Humans, Medicine, Cytotoxic T cell, Hypersensitivity, Delayed, Child, chemistry.chemical_classification, Acute leukemia, biology, business.industry, In vitro, Leukemia, Lymphoid, Leukemia, Myeloid, Acute, Enzyme, Oncology, chemistry, Concomitant, Antibody Formation, Immunology, biology.protein, Drug Therapy, Combination, Antibody, business
Abstract

One hundred and fourteen patients with acute leukemia, 57 children (10 AML and 47 ALL) and 57 adults (37 AML and 20 ALL) were treated with L-asparaginase (Asnase) 200 or 1000 IU/kg daily for 30 days unless withdrawn on account of side effects. Combinations with other cytotoxic drugs were used in all but eight patients. Hypersensitive reactions, decrease in Asnase activity in plasma, and bivalent antibodies to Asnase appeared more frequently in adults (28%, 46%, and 79%, respectively) than in children (16%, 17%, and 25% respectively). There was a clear association between these three parameters. Thus hypersensitive reactions generally developed at the time of or after the decrease in plasma Asnase activity. Antibodies were detected only where Asnase activity had disappeared from the plasma. This time sequence, and in vitro experiments, suggest the formation of antigen-antibody complexes which might be responsible for inactivation of Asnase and for the development of hypersensitive reactions. However in many cases antibodies were found without concomitant enzyme inactivation or hypersensitive reactions. Antibodies to Asnase of IgE type (reagins) were found in only 10 children and 6 adults. There was no correlation between hypersensitive reactions, decrease in Asnase activity, and IgE antibodies. The frequency of remission among patients developing bivalent antibodies to Asnase was 68% (13/19) in contrast to 27% (3/11) among patients whose sera contained no detectable antibodies to Asnase, but the difference was not statistically significant.

Published
1976
Full Text
View/download PDF

19. Induction of remission with l-asparaginase, cyclophosphamide, cytosine arabinoside, and prednisolone in adult patients with acute leukemia

Author

Gahrton, G., primary, Engstedt, L., additional, Franzén, S., additional, Gullbring, B., additional, Holm, G., additional, Höglund, S., additional, Killander, A., additional, Killander, D., additional, Lockner, D., additional, Mellstedt, H., additional, Palmblad, J., additional, Reizenstein, P., additional, Skarberg, K-O., additional, Swedberg, B., additional, and Udén, A-M., additional

Published
1974
Full Text
View/download PDF

22. Immune phenotype heterogeneity in AML

Author

Öst, Å., primary, Christensson, B., additional, Andreasen, R., additional, Hast, R., additional, Lagerlöf, B., additional, Reizenstein, P., additional, Trowbridge, I. S., additional, and Biberfeld, P., additional

Published
1985
Full Text
View/download PDF

23. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

Author

Killander, D., primary, Dohlwitz, A., additional, Engstedt, L., additional, Franzén, S., additional, Gahrton, G., additional, Gullbring, B., additional, Holm, G., additional, Holmgren, A., additional, Höglund, S., additional, Killander, A., additional, Lockner, D., additional, Mellstedt, H., additional, Moe, P. J., additional, Palmblad, J., additional, Reizenstein, P., additional, Skårberg, K.-O., additional, Swedberg, B., additional, Udén, A.-M., additional, Wadman, B., additional, Wide, L., additional, and Åhström, L., additional

Published
1976
Full Text
View/download PDF

24. L‐Asparaginase and Prednisolone Pretreatment Followed by Rubidomycin and Cytosine Arabinoside for Induction of Remission in Adult Patients with Acute Myeloblastic Leukaemia

Author

Udén, A.‐M., primary, Brenning, G., additional, Engstedt, L., additional, Franzén, S., additional, Gahrton, G., additional, Gullbring, B., additional, Holm, G., additional, Höglund, S., additional, Jameson, S., additional, Killander, A., additional, Killander, D., additional, Lockner, D., additional, Wellstedt, H., additional, Palmblad, J., additional, Reizenstein, P., additional, Skårberg, K.‐O., additional, Swedberg, B., additional, Wadman, B., additional, and Wide, L., additional

Published
1975
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results